drugset / Trial / NCT00209677

Phase I/II Study of Oral S-1 Plus Gemcitabine in Patients With Metastatic Pancreatic Cancer

NCT00209677

Non-randomizedSingle-groupOpen-labelTreatment

Summary

To assess the usefulness of Gemcitabine plus S-1 therapy based on the antitumor effect and survival period. By performing a phase I/II study of this combination in patients with inoperable or with postoperative pancreatic cancer.

Timeline

Start
2004-12
Primary completion
Completion
2007-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Gemcitabine Small molecule
Subject S-1 Small molecule